Volume 63, Issue 6, Pages (June 2003)

Slides:



Advertisements
Similar presentations
Volume 65, Issue 1, Pages (January 2004)
Advertisements

Volume 63, Issue 6, Pages (June 2003)
Volume 64, Issue 6, Pages (December 2003)
Volume 80, Issue 7, Pages (October 2011)
Volume 66, Issue 3, Pages (September 2004)
Volume 71, Issue 3, Pages (February 2007)
Volume 62, Issue 2, Pages (August 2002)
Volume 64, Issue 1, Pages (July 2003)
J.M. Henderson, S. al-Waheeb, A. Weins, S.V. Dandapani, M.R. Pollak 
Volume 65, Issue 1, Pages (January 2004)
Volume 68, Issue 5, Pages (November 2005)
Volume 58, Issue 6, Pages (December 2000)
Volume 75, Issue 10, Pages (May 2009)
Volume 65, Issue 6, Pages (June 2004)
Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice
Volume 54, Issue 4, Pages (October 1998)
Volume 66, Issue 5, Pages (November 2004)
Volume 63, Issue 6, Pages (June 2003)
Volume 57, Issue 6, Pages (June 2000)
Volume 56, Issue 6, Pages (December 1999)
Volume 54, Issue 3, Pages (September 1998)
Volume 87, Issue 1, Pages (January 2015)
Volume 77, Issue 11, Pages (June 2010)
Volume 61, Issue 5, Pages (May 2002)
Volume 69, Issue 1, Pages (January 2006)
The intrarenal renin-angiotensin system in hypertension
Volume 59, Issue 5, Pages (May 2001)
Volume 59, Issue 4, Pages (April 2001)
Hiroyuki Yanagisawa, Nobuyuki Yamazaki, Gen Sato, Osamu Wada 
Volume 58, Issue 1, Pages (July 2000)
Volume 63, Issue 5, Pages (May 2003)
Volume 70, Issue 8, Pages (October 2006)
Isotretinoin alleviates renal damage in rat chronic glomerulonephritis
Volume 63, Issue 2, Pages (February 2003)
Volume 57, Issue 1, Pages (January 2000)
Volume 60, Issue 6, Pages (December 2001)
Volume 53, Issue 5, Pages (May 1998)
Calcium citrate ameliorates the progression of chronic renal injury
Volume 70, Issue 7, Pages (October 2006)
Tight blood pressure control decreases apoptosis during renal damage
Volume 83, Issue 6, Pages (June 2013)
Volume 64, Pages S64-S70 (October 2003)
Volume 79, Issue 4, Pages (February 2011)
Volume 61, Issue 6, Pages (June 2002)
Volume 63, Issue 4, Pages (April 2003)
Volume 67, Issue 4, Pages (April 2005)
Volume 69, Issue 12, Pages (June 2006)
Macrophages and hypoxia in human chronic kidney disease
Expression of connective tissue growth factor in human renal fibrosis
Volume 58, Issue 6, Pages (December 2000)
Volume 67, Issue 2, Pages (February 2005)
C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis  Gopala K. Rangan, Jeffrey W. Pippin, William.
Volume 71, Issue 9, Pages (May 2007)
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Volume 78, Issue 1, Pages (July 2010)
Volume 59, Issue 5, Pages (May 2001)
Volume 67, Issue 3, Pages (March 2005)
M.-J. Wu, M.-C. Wen, Y.-T. Chiu, Y.-Y. Chiou, K.-H. Shu, M.-J. Tang 
Volume 65, Issue 6, Pages (June 2004)
Volume 69, Issue 11, Pages (June 2006)
Interferon-γ inhibits experimental renal fibrosis
Volume 58, Issue 3, Pages (September 2000)
Why is proteinuria an ominous biomarker of progressive kidney disease?
Volume 58, Issue 4, Pages (October 2000)
Volume 59, Issue 5, Pages (May 2001)
Increased importin α protein expression in diabetic nephropathy
Is it the low-protein diet or simply the salt restriction?
Volume 58, Issue 3, Pages (September 2000)
Volume 75, Issue 5, Pages (March 2009)
Renoprotection with vitamin D: Specific for diabetic nephropathy?
Presentation transcript:

Volume 63, Issue 6, Pages 2162-2170 (June 2003) Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy  Ulf Janssen, Stephen G. Riley, Athina Vassiliadou, Jürgen Floege, Aled O. Phillips  Kidney International  Volume 63, Issue 6, Pages 2162-2170 (June 2003) DOI: 10.1046/j.1523-1755.2003.00007.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Systolic blood pressure in Goto Kakizaki (GK) (A) and Wistar rats (B) 1 week before and every 2 weeks after start of treatment with deoxycorticosterone acetate (DOCA) salt (■), vehicle salt (▴), or DOCA tap water (▾).*P < 0.05 vs. control. Kidney International 2003 63, 2162-2170DOI: (10.1046/j.1523-1755.2003.00007.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Proteinuria in Goto Kakizaki (GK) (A) and Wistar rats (B) 1 week before and every 4 weeks after start of treatment with deoxycorticosterone acetate (DOCA) salt (■), vehicle salt (▴), or DOCA tap water (▾).*P < 0.05 vs. controls; **P < 0.05 vs. DOCA salt–treated Wistar rats and controls. Kidney International 2003 63, 2162-2170DOI: (10.1046/j.1523-1755.2003.00007.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Glomerular histologic findings in Goto Kakizaki (GK) and Wistar rats 15 and 24 weeks after start of treatment with DOCA salt (■), vehicle-salt (), or DOCA-tap water (□). Quantitative assessment of glomerulosclerosis (%) (A). Immunostaining scores for type IV collagen (B), α-smooth muscle actin (α-SMA) (C), and desmin (D). Monocyte/macrophage influx: counts of ED1-positive monocytes/macrophages (E). Cell proliferation: counts of BrdU-positive cells (F). ND = not determined. Kidney International 2003 63, 2162-2170DOI: (10.1046/j.1523-1755.2003.00007.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 4 Renal desmin immunostaining. (A) A nonhypertensive Goto Kakizaki (GK) control rat 24 weeks after start of treatment with vehicle salt. Desmin expression is confined to the mesangium. (B) A hypertensive Wistar rat 24 weeks after start of treatment with deoxycorticosterone acetate (DOCA) salt. Desmin expression mostly exhibits a normal pattern in that it is confined to the mesangium. However, focal up-regulation is present in two podocytes at the edge of the glomerular tuft (arrows). (C) A hypertensive GK rat 24 weeks after start of treatment with DOCA salt. Glomerular desmin expression is markedly up-regulated predominantely at the glomerular edge. Kidney International 2003 63, 2162-2170DOI: (10.1046/j.1523-1755.2003.00007.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 5 Electron microscopy findings. (A) Hypertensive Goto Kakizaki (GK) rat 24 weeks after start of treatment with deoxycorticosterone acetate (DOCA) salt. This shows podocytes with foot process effacement (arrowheads) as well as dense bodies (arrows). (B) Hypertensive GK rat 24 weeks after start of treatment with DOCA salt. Podocytes with microvilli formation (arrowheads) and lamella bodies (arrows). Kidney International 2003 63, 2162-2170DOI: (10.1046/j.1523-1755.2003.00007.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 6 Tubulointerstitial histologic findings in Goto Kakizaki (GK) and Wistar rats 15 and 24 weeks after start of treatment with deoxycorticosterone (DOCA) salt (■), vehicle salt (), or DOCA tap water (□). Quantitative assessment of tubulointerstitial damage (A). Immunostaining scores for type IV collagen (B) and α-smooth muscle actin (α-SMA) (C). Monocyte/macrophage influx: counts of ED1-positive monocytes/macrophages (D). Cell proliferation: counts of BrdU-positive cells (E). Immunostaining score for monocyte chemoattractant protein-1 (MCP-1) (F). ND = not determined. Kidney International 2003 63, 2162-2170DOI: (10.1046/j.1523-1755.2003.00007.x) Copyright © 2003 International Society of Nephrology Terms and Conditions